Sample Mining and Data Mining: Combined Real‐Time and Retrospective Approaches for the Identification of Emerging Novel Psychoactive Substances

Novel psychoactive substances (NPS) are synthetic drugs that pose serious public health and safety concerns. A multitude of NPS have been identified in the United States, often implicated in forensic investigations. The most common and effective manner for identifying NPS is by use of mass spectrometry and the true utility lies within nontargeted acquisition techniques. During this study, a liquid chromatography quadrupole time‐of‐flight mass spectrometry (LC‐QTOF‐MS) assay was developed, validated, and implemented for forensic toxicology testing. A SCIEX TripleTOF™ 5600 + with SWATH® acquisition was used. Resulting data were compared against an extensive library database containing more than 800 compounds. The LC‐QTOF‐MS assay was applied to the reanalysis of biological sample extracts to discover emergent NPS. More than 3,000 sample extracts were analyzed, and more than 20 emerging NPS were detected for the first time. Among these were isopropyl‐U‐47700, 3,4‐methylenedioxy‐U‐47700, fluorofuranylfentanyl, N‐methyl norfentanyl, 2F‐deschloroketamine, 3,4‐methylenedioxy‐alpha‐PHP, eutylone, and N‐ethyl hexedrone.

[1]  C. Morgan,et al.  Ketamine use: a review. , 2012, Addiction.

[2]  Ju‐Seop Kang Principles and Applications of LC-MS/MS for the Quantitative Bioanalysis of Analytes in Various Biological Samples , 2012 .

[3]  Alan H B Wu,et al.  High-Resolution Mass Spectrometry for Untargeted Drug Screening. , 2016, Methods in molecular biology.

[4]  E. Schneider,et al.  Opioid activity and distribution of fentanyl metabolites , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.

[5]  Aaron A. Urbas,et al.  NPS Data Hub: A web-based community driven analytical data repository for new psychoactive substances , 2018, Forensic Chemistry.

[6]  Y. Sarne,et al.  On the opioid nature of phencyclidine and its 3-hydroxy derivative. , 1981, European journal of pharmacology.

[7]  G. L. Henderson,et al.  Designer drugs: past history and future prospects. , 1988, Journal of forensic sciences.

[8]  Tadessa Harper-Nichols Prescription Drug Monitoring Program. , 2014, Journal of the California Dental Association.

[9]  C. Herrmann,et al.  Analysis of new designer drugs and common drugs of abuse in urine by a combined targeted and untargeted LC-HR-QTOFMS approach , 2014, Analytical and Bioanalytical Chemistry.

[10]  E. Freye Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs , 2010 .

[11]  B. Logan,et al.  N-Ethyl Pentylone (Ephylone) Intoxications: Quantitative Confirmation and Metabolite Identification in Authentic Human Biological Specimens. , 2018, Journal of analytical toxicology.

[12]  C. McKay,et al.  Ketamine abusers presenting to the emergency department: a case series. , 2000, The Journal of emergency medicine.

[13]  M. Huestis,et al.  Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review. , 2017, Journal of analytical toxicology.

[14]  J. Prasain Tandem Mass Spectrometry - Applications and Principles , 2012 .

[15]  David E. Smith,et al.  The New Designer Drug Wave: A Clinical, Toxicological, and Legal Analysis , 2015, Journal of psychoactive drugs.

[16]  Jeri D Ropero-Miller,et al.  The Opioid Epidemic: Moving Toward an Integrated, Holistic Analytical Response. , 2018, Journal of analytical toxicology.

[17]  M. Tsokos,et al.  A Fatal Case Involving N-Ethyldeschloroketamine (2-Oxo-PCE) and Venlafaxine. , 2018, Journal of analytical toxicology.

[18]  Thomas Kraemer,et al.  Liquid chromatography, in combination with a quadrupole time-of-flight instrument (LC QTOF), with sequential window acquisition of all theoretical fragment-ion spectra (SWATH) acquisition: systematic studies on its use for screenings in clinical and forensic toxicology and comparison with informatio , 2014, Analytical chemistry.

[19]  Carla Lewandowski,et al.  Information Sharing Using a State Fusion Center: A Case Study of the New Jersey Regional Operations Intelligence Center , 2012 .

[20]  B. Thomas,et al.  Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs. , 2012, Analytical chemistry.

[21]  U. Garg Clinical Applications of Mass Spectrometry in Drug Analysis , 2016, Methods in Molecular Biology.

[22]  Leonard J Paulozzi,et al.  Prescription drug monitoring programs and death rates from drug overdose. , 2011, Pain medicine.

[23]  Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology. , 2013, Journal of analytical toxicology.

[24]  R. Subramanian,et al.  Comparison of information-dependent acquisition, SWATH, and MS(All) techniques in metabolite identification study employing ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. , 2014, Analytical chemistry.

[25]  R. Gerona,et al.  Non-targeted screening for novel psychoactive substances among agitated emergency department patients , 2016, Clinical toxicology.

[26]  N. Volkow,et al.  Abuse of New Psychoactive Substances: Threats and Solutions , 2016, Neuropsychopharmacology.

[27]  Herbert Oberacher,et al.  Applying ‘Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra’ (SWATH) for systematic toxicological analysis with liquid chromatography-high-resolution tandem mass spectrometry , 2014, Analytical and Bioanalytical Chemistry.

[28]  K. Redda,et al.  Cocaine, Marijuana, Designer Drugs: Chemistry, Pharmacology, and Behavior , 1989 .

[29]  D. Deforce,et al.  Simultaneous, quantitative determination of opiates, amphetamines, cocaine and benzoylecgonine in oral fluid by liquid chromatography quadrupole-time-of-flight mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[30]  H. Maurer Multi-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography-single stage or tandem mass spectrometry (LC-MS or LC-MS/MS) relevant to clinical and forensic toxicology. , 2005, Clinical biochemistry.

[31]  C. Kostakis,et al.  A Case Study Involving U-47700, Diclazepam and Flubromazepam-Application of Retrospective Analysis of HRMS Data. , 2018, Journal of analytical toxicology.

[32]  S. Johansen,et al.  Simultaneous screening and quantification of 52 common pharmaceuticals and drugs of abuse in hair using UPLC-TOF-MS. , 2010, Forensic science international.

[33]  P. Hydzik,et al.  Fetal death associated with the use of 3,4-MDPHP and α-PHP , 2018, Clinical toxicology.

[34]  Markus Müller,et al.  Processing strategies and software solutions for data‐independent acquisition in mass spectrometry , 2015, Proteomics.

[35]  D. Jerrard "Designer drugs"--a current perspective. , 1990, The Journal of emergency medicine.

[36]  G. Janis,et al.  Identification of Unique Metabolites of the Designer Opioid Furanyl Fentanyl. , 2017, Journal of analytical toxicology.

[37]  Christian Brinch Mollerup,et al.  Targeted and non-targeted drug screening in whole blood by UHPLC-TOF-MS with data-independent acquisition. , 2017, Drug testing and analysis.

[38]  R. Dinis-Oliveira Metabolism and metabolomics of ketamine: a toxicological approach , 2017, Forensic sciences research.

[39]  Matt Anderson,et al.  European Monitoring Centre for Drugs and Drug Addiction , 2014 .

[40]  A. Janowsky,et al.  Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters , 2018, Psychopharmacology.

[41]  John B. Fenn,et al.  Electrospray ionization–principles and practice , 1990 .

[42]  G. Hanson,et al.  Fentanyl receptor assay. II. Utilization of a radioreceptor assay for the analysis of fentanyl analogs in urine. , 1992, Journal of analytical toxicology.